Previous 10 | Next 10 |
Bluebird bio (NASDAQ: BLUE ) provides an update in response to the global COVID-19 pandemic. More news on: bluebird bio, Inc., Healthcare stocks news, Read more ...
- Company to hold investor conference call today, March 26, 2020 at 8:30 am ET – bluebird bio, Inc. (NASDAQ: BLUE) today provided an update in response to the global COVID-19 pandemic. The company has taken steps to ensure the safety of its patients and employees, while worki...
Introduction Sangamo Therapeutics ( SGMO ) is a clinical-stage biotech company focusing on the research and development of genomic medicine across 4 distinct technology platforms: gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. Sangamo is best-known for...
Biopharmaceutical stocks are taking another serious beating today. Shares of BioMarin Pharmaceutical (NASDAQ: BMRN) fell by as much as 10%, Bristol-Myers Squibb 's (NYSE: BMY) stock dipped by 12.7%, and bluebird bio (NASDAQ: BLUE) lost 18.7% of its value in early-morning trading. For...
Biotech and biopharma stocks regained their footing last Friday after a historically brutal week. For instance, shares of AnaptysBio (NASDAQ: ANAB) closed up by 12.5% last Friday; bluebird bio (NASDAQ: BLUE) stock posted a modest 2.17% gain after dipping by as much ...
Shares of several biotech stocks were sinking on Thursday due to a major market sell-off related to increased worries about the impact of the coronavirus disease COVID-19. AnaptysBio (NASDAQ: ANAB) stock was down 8.2% as of 11:38 a.m. EDT after falling as much as 16.4% earlier in the day. Sh...
Introduction Celyad ( CYAD ) is a clinical-stage biopharmaceutical company, focusing on the development of CAR-T cell therapy for treating cancers. The company has both autologous and allogeneic technological platforms for CAR-T and has 2 international partnerships with Novartis and Horizo...
Introduction Precision BioSciences ( DTIL ) is a genome editing company dedicated to improving life through their proprietary genome editing platform (“ARCUS”), where they are developing product candidates in three high-value areas: allogeneic CAR T immunotherapy, in vivo g...
Nearly 1.8 million Americans were diagnosed with cancer last year. Around the world, the total was close to 17 million. It's not surprising, then, that more than 700 biopharmaceutical companies have experimental cancer drugs in late-stage development. Beta-thalassemia, on the other hand, is a...
There has been so much progress in treating cancer in just the past 10 years that it could make your head spin. Researchers have identified new ways to fight cancer -- and new ways to diagnose cancer more effectively, too. Close to $150 billion will likely be spent on cancer drugs this year. Th...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...